Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sorrento Therapeutics, Inc. - Common Stock (NQ:SRNE)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sorrento Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
7 of the Best Contrarian Stocks to Buy When Investors Are Fearful
For those who are interested in taking up the challenge of being contrarian investors, here are seven contrarian stocks to buy. 
Via InvestorPlace
Why Sorrento Therapeutics Stock Is on the Rise Today
The drugmaker's stock is moving upward today in sympathy with the broader biopharmaceutical industry. 
Via The Motley Fool
What Is Going on With NewAge (NBEV) Stock Today?
NewAge (NBEV) stock is in the spotlight Wednesday after the company filed for Chapter 11 bankruptcy protection as it seeks a sale. 
Via InvestorPlace
Sorrento Therapeutics (SRNE) Pops on FDA Fast Track Designation
Sorrento Therapeutics (SRNE) stock is getting a boost on Wednesday after the FDA granted it fast-track designation for SP-103. 
Via InvestorPlace
Why Cepton Is Trading Higher By 19%; Here Are 28 Stocks Moving Premarket
Gainers Software Acquisition Group Inc. III (NASDAQ: NOGN) shares rose 80.1% to $6.04 in pre-market trading after dropping over 65% on Tuesday. 
Via Benzinga
FDA Clears Sorrento's STI-1558 Phase 1 Study To Treat COVID-19 Infection
Via Benzinga
Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Sorrento Shares Pop After Interim Data From Lung Cancer Trial
Sorrento Therapeutics Inc (NASDAQ: SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured... 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
10 Stocks to Sell Before They Die
As the U.S. continues to struggle with stagflation, it’s becoming more important than ever to avoid pitfalls. 
Via InvestorPlace
The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low. 
Via Benzinga
FDA Gives Green Signal To Human Trial For Sorrento's STI-9167 Against Omicron
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness... 
Via Benzinga
Sorrento Shares Gain Following FDA's Nod for Initial-Stage Covid-19 Study
Sorrento Therapeutics (NASDAQ: SRNE) announced that the U.S. Food and Drug Administration (FDA) has cleared the Phase 1 study of its candidate, STI-1558, in patients with impaired renal and hepatic... 
Via Benzinga
Epizyme + 20 Stocks Moving In Monday's Pre-Market Session
Gainers Tenax Therapeutics, Inc. (NASDAQ: TENX) rose 90.1% to $0.59 in pre-market trading after dipping more than 46% on Friday. 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
Sorrento To Start Late-Stage Trial Of Abivertinib In Critically-Ill COVID-19 Patients
Via Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
Sorrento's Scilex Unit Begins Mid-stage Study of Lower Back Pain Drug
Scilex Holding Company, a Sorrento Company (NASDAQ: SRNE) announced dosing of the first patient in a Phase 2 study of its drug candidate in patients with SP-103 in subjects with acute low back pain... 
Via Benzinga
The Biotech Company That's Training Immune Cells To Fight Cancer
Photo by National Cancer Institute on Unsplash Dr. Henry Ji, President and CEO of Sorrento Therapeutics (NASDAQ: SRNE), was a guest speaker at Benzinga’s All Access on March 25, 2022. 
Via Benzinga
67 Biggest Movers From Yesterday
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital. 
Via Benzinga
Sorrento Therapeutics shares are trading high following FDA clearance of IND for Abivertinib in metastatic castrate resistant prostate cancer (mCRPC)
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug application (IND) of Abivertinib (Fujovee) for patients... 
Via Benzinga
71 Biggest Movers From Yesterday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares jumped 225% to close at $4.68 on Wednesday after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration... 
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 236 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 242 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was... 
Via Benzinga
10 Biggest Price Target Changes For Friday
Jefferies cut the price target on MEI Pharma, Inc. (NASDAQ: MEIP) from $4 to $1. MEI Pharma shares fell 44.2% to $1.01 in pre-market trading. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.